The shaper of Wegovy and Ozempic, Novo Nordisk, has launched ineligible enactment accusing its arch rival Eli Lilly of mendacious advertizing successful suggesting its weight-loss drugs execute better.
The Danish institution filed a suit successful the US connected Tuesday claiming Eli Lilly, which makes Mounjaro and Zepbound, deployed advertisement campaigns to "create the misleading content that Eli Lilly's medicines are superior".
Novo said its rival compared the highest approved doses of its medicines for obesity and type-2 diabetes with little doses of Novo Nordisk's, portion omitting newer, higher-dose options.
The BBC has contacted Eli Lilly for comment.
The suit comes arsenic Novo and Eli Lilly are locked successful conflict to predominate the fast--growing weight-loss cause industry, particularly successful the US, which analysts person estimated could beryllium worthy much than $100bn by 2030.
Novo Nordisk claimed its main rival successful the weight-loss cause concern had committed "multiple violations" of national and authorities mendacious advertizing and unfair contention laws, done its nationwide advertisement campaigns.
The institution said Eli Lilly's existent campaigns "intentionally" selected outdated studies comparing Lilly's highest doses against little doses of Novo Nordisk's medicines.
It said the ads had "deceptively" presented that Eli Lilly's products were superior, but buried oregon omitted "critical objective context".
The products being compared incorrectly, according to Novo, were Mounjaro vs. Ozempic and Zepbound vs Wegovy.
"As caller and much effectual attraction options go available, radical merit close accusation that reflects the latest technological grounds and helps them marque informed attraction decisions," said John F. Kuckelman, elder vice president and radical wide counsel for Novo Nordisk.
"Healthcare companies person a work to support their nationalist claims close and existent - ineffective, fine-print disclaimers bash not hole the misleading content created by large nationalist campaigns," helium said.
Novo said it was seeking a tribunal bid requiring Eli Lilly to propulsion its ads and alternatively tally what it called a "corrective advertizing campaign".
It added if Eli Lilly did not voluntarily region the commercials, it would record a question successful the coming days to question a preliminary injunction to artifact them.
English (US)·